56256-14-5

Usage

Chemical Properties

off-white powder

InChI:InChI=1/C8H7BrO3/c1-12-7-4-5(8(10)11)2-3-6(7)9/h2-4H,1H3,(H,10,11)

Upstream product

• 50870-44-5 1-(4-bromo-3-methoxyphenyl)ethanone 
• 586-38-9 3-Methoxybenzoic acid 
• 50870-42-3 4,4,8,8-Tetrabrom-1-methoxytricyclo<5.1.0.0^3,5>octan 
• 14348-38-0 4-bromo-3-hydroxybenzoic acid 
• 99-06-9 3-Carboxyphenol 
• 106291-80-9 methyl 4-bromo-3-hydroxybenzoate 
• 17100-63-9 methyl 4-bromo-3-methoxybenzoate 
• 2486-69-3 3-methoxy-4-aminobenzoic acid 
• 43192-34-3 4-bromo-3-methoxybenzaldehyde 

Downstream Products

• 56256-15-6 4-bromo-3-methoxy-benzoyl chloride 
• 74733-24-7 4-formyl-3-methoxybenzoic acid methyl ester 
• 1309682-36-7 4-bromo-N-(2-hydroxyethyl)-3-methoxybenzamide 
• 1309682-37-8 4-bromo-N-(2-hydroxy-2-methylpropyl)-3-methoxybenzamide 
• 1309682-38-9 4-bromo-N-(1-hydroxy-2-methylpropan-2-yl)-3-methoxybenzamide 
• 1309682-39-0 4-bromo-N-(2-ethoxyethyl)-3-methoxybenzamide 
• 1309682-40-3 4-bromo-3-methoxy-N-methyl-N-[2-(methylamino)ethyl]benzamide 
• 1309682-41-4 N-{2-[acetyl(methyl)amino]ethyl}-4-bromo-3-methoxy-N-methylbenzamide 
• 1309682-42-5 tert-butyl {2-[(4-bromo-3-methoxybenzoyl)(methyl)amino]ethyl}methyl-carbamate 
• 1309682-43-6 4-bromo-3-methoxy-N-(2,2,2-trifluoroethyl)benzamide 
• 1309682-44-7 4-bromo-3-methoxy-N-[2-(methylsulfonyl)ethyl]benzamide 
• 1403330-38-0 4-{[6-(4-{[(4-fluorophenyl)acetyl]amino}phenyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino}-N-(2-hydroxyethyl)-3-methoxybenzamide 
• 1403330-44-8 4-{[6-{4-{[(4-fluorophenyl)acetyl]amino}phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino}-N-(2-hydroxy-2-methylpropyl)-3-methoxybenzamide 
• 1403330-70-0 4-[(6-{4-[(4-fluorobenzyl)carbamoyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)amino]-N-(2-hydroxyethyl)-3-methoxybenzamide 

Relevant academic research and scientific papers

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS

The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.

Bifunctional organocatalysts for the asymmetric synthesis of axially chiral benzamides

Bifunctional organocatalysts bearing amino and urea functional groups in a chiral molecular skeleton were applied to the enantioselective synthesis of axially chiral benzamides via aromatic electrophilic bromination. The results demonstrate the versatilit

Elongated and substituted triazine-based tricarboxylic acid linkers for MOFs

New triazine-based tricarboxylic acid linkers were prepared as elongated relatives of triazinetribenzoic acid (TATB). Additionally, functional groups (NO2, NH2, OMe, OH) were introduced for potential post-synthetic modification (PSM) of MOFs. Functionalized tris(4-bromoaryl)triazine "cores" (3a,3b) were obtained by unsymmetric trimerization mixing one equivalent of an acid chloride (OMe or NO2 substituted) with two equivalents of an unsubstituted nitrile. Triple Suzuki coupling of the cores 3 with suitable phenyl- and biphenylboronic acid derivatives provided elongated tricarboxylic acid linkers as carboxylic acids 17 and 20 or their esters 16 and 19. Reduction of the nitro group and cleavage of the methoxy group gave the respective amino and hydroxy-substituted triazine linkers.

METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES

The present invention relates to methods of preparing substituted triazolopyridine compounds of general formula (I) as described and defined herein, as well as to intermediate compounds useful in the preparation of said compounds.

METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES

The present invention relates to methods o f preparing substituted triazolopyridine compounds of general formula (I) as described and defined herein, as well as to intermediate compounds useful in the preparation of said compounds.

NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER

The present invention relates to novel compounds showing an inhibitory effect on Mps-1 kinase, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

SUBSTITUTED TRIAZOLOPYRIDINES HAVING ACTIVITY AS MPS-1 INHIBITORS

The present invention relates to substituted triazolopyridine compounds of general formula (I), in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS

The present invention relates to substituted triazolopyndine compounds of general formula (I) : in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

TRIAZOLOPYRIDINES

The present invention relates to triazolopyridine compounds of general formula (I) : in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said com